Infliximab

Biogen is still evaluating launch timeline for Tofidence, and information on pricing will be available closer to launch.

Sandoz will now launch both high-concentration and low-concentration versions of Hyrimoz (adalimumab-adaz) in July.

Kevzara is the first biologic to treat patients with polymyalgia rheumatica (PMR). It is also approved to treat rheumatoid arthritis.

The real impact may not likely be seen until after July when additional biosimilars referencing Humira are launched.

Some PBMs will offer Amgen’s Amjevita biosimilar as a preferred product alongside Humira, but CVS Caremark said Humira will remain preferred and Amjevita will be placed on a non-preferred brand tier.

A decision is anticipated in early January about which of the now eight Humira biosimilars will be included.